A systematic review of natural health product treatment for vitiligo by Szczurko, Orest & Boon, Heather S
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Dermatology
Open Access Research article
A systematic review of natural health product treatment for vitiligo
Orest Szczurko and Heather S Boon*
Address: Leslie Dan Faculty of Pharmacy, University of Toronto, Canada
Email: Orest Szczurko - oszczurko@utoronto.ca; Heather S Boon* - heather.boon@utoronto.ca
* Corresponding author    
Abstract
Background: Vitiligo is a hypopigmentation disorder affecting 1 to 4% of the world population.
Fifty percent of cases appear before the age of 20 years old, and the disfigurement results in
psychiatric morbidity in 16 to 35% of those affected.
Methods: Our objective was to complete a comprehensive, systematic review of the published
scientific literature to identify natural health products (NHP) such as vitamins, herbs and other
supplements that may have efficacy in the treatment of vitiligo. We searched eight databases
including MEDLINE and EMBASE for vitiligo, leucoderma, and various NHP terms. Prospective
controlled clinical human trials were identified and assessed for quality.
Results: Fifteen clinical trials were identified, and organized into four categories based on the NHP
used for treatment. 1) L-phenylalanine monotherapy was assessed in one trial, and as an adjuvant
to phototherapy in three trials. All reported beneficial effects. 2) Three clinical trials utilized
different traditional Chinese medicine products. Although each traditional Chinese medicine trial
reported benefit in the active groups, the quality of the trials was poor. 3) Six trials investigated the
use of plants in the treatment of vitiligo, four using plants as photosensitizing agents. The studies
provide weak evidence that photosensitizing plants can be effective in conjunction with
phototherapy, and moderate evidence that Ginkgo biloba monotherapy can be useful for vitiligo. 4)
Two clinical trials investigated the use of vitamins in the therapy of vitiligo. One tested oral
cobalamin with folic acid, and found no significant improvement over control. Another trial
combined vitamin E with phototherapy and reported significantly better repigmentation over
phototherapy only. It was not possible to pool the data from any studies for meta-analytic purposes
due to the wide difference in outcome measures and poor quality ofreporting.
Conclusion:  Reports investigating the efficacy of NHPs for vitiligo exist, but are of poor
methodological quality and contain significant reporting flaws. L-phenylalanine used with
phototherapy, and oral Ginkgo biloba as monotherapy show promise and warrant further
investigation.
Background
Vitiligo is a hypopigmentation disorder where the loss of
functioning melanocytes causes the appearance of white
patches on the skin. Vitiligo affects 1% of the world pop-
ulation [1], but the prevalence has been reported as high
as 4% in some South Asian, Mexican and American pop-
ulations [2,3]. Vitiligo can develop at any age, but several
studies report that 50% of cases appear before the age of
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20 [4-6]. Barona found that in patients with unilateral
vitiligo the mean age at onset was 16.3 years (95% CI: 12
to 19 years), compared to 24.8 years (95% CI: 22 to 28
years) in patients with bilateral vitiligo [7].
Sixteen to 35% of patients with vitiligo experience signifi-
cant psychiatric morbidity [8]. Depression (10%), dys-
thymia (7–9%), sleep disturbances (20%), suicidal
thoughts (10%), suicidal attempts (3.3%) and anxiety
(3.3%) have been found in those affected with vitiligo [8].
Vitiligo can also lead to difficulties in forming relation-
ships, avoidance of certain social situations, and difficul-
ties in sexual relationships [9]. Vitiligo can be confused
with leprosy, which also causes loss of pigment, thus fur-
ther stigmatizing patients [10].
Several systematic reviews assessing the clinical efficacy of
topical corticosteroids, narrowband ultraviolet light B
(UVB), psoralen with ultraviolet light A exposure (PUVA),
calcipotriol, l-phenylalanine, topical immunomodulators
(tacrolimus and pimecrolimus), excimer laser, and surgi-
cal therapy in the management of symptoms associated
with vitiligo have recently been published, including in
the Journal of the American Medical Association (JAMA)
and by the Cochrane Collaboration [1,11,12]. These
reviews conclude that there is some evidence that topical
steroids are of benefit, but report concerns with long term
side effects of topical steroids. The review authors also
report some evidence for the efficacy of phototherapy
(UVA or UVB) as a monotherapy, or combined with pso-
ralens or calcipotriol. However, concerns are raised about
side effects such as phototoxic reactions, blistering, and
lack of data on long term skin cancer risk. All three system-
atic reviews conclude that use of topical immunomondu-
lators shows promise, but that further evaluation is
needed. In addition, the systematic review by Whitton [1]
performed for the Chochrane collaboration and the sys-
tematic review published by Forschner [11] in JAMA indi-
cate that L-phenylalanine use with phototherapy appears
promising, but that more research is necessary before firm
conclusions can be drawn.
Although many clinical trials examining the use of natural
health product (NHP) interventions (e.g., vitamins, min-
erals, herbal medicines and other supplements) for vitil-
igo have been published, we were unable to find any
systematic reviews of these. Here we report the results of a
systematic review of controlled clinical trials investigating
the efficacy of NHPs in the treatment of vitiligo.
Methods
Our objective was to complete a comprehensive, system-
atic review of the published scientific literature to identify
NHPs that may have efficacy in the treatment of vitiligo.
The databases and search terms used are listed in Table 1.
All databases were searched for all available years up to
August 27, 2007. The first two items (vitiligo, leuco-
derma) were searched individually in each database and
combined together using the "OR" boolean. All search
terms except the first two (vitiligo, leucoderma) were
searched individually in each database and combined
together using the "OR" boolean. The results from the
searches of the first two bullets were then combined with
the rest of the search terms by utilizing the "AND"
boolean.
The resulting list was assessed for inclusion and exclusion
criteria based on title and abstract. Full reports of the stud-
ies that matched the inclusion criteria were collected,
translated where necessary, and re-assessed to make a final
decision regarding inclusion or exclusion. The assessment
process was completed by OS, in consultation with HB.
This systematic review included prospective controlled
clinical human trials. Randomization was not a require-
ment for inclusion in the review. Only studies which used
NHPs as defined by Health Canada [13] were selected.
Essentially, Health Canada defines any compound found
in nature that is used for health purposes as a NHP includ-
ing: vitamins, minerals, and any product derived from a
plant, animal, fungi or algae. In addition, the patients in
the trials must have been diagnosed with any form of vitil-
igo as defined by Merck [14]. The Merck manual defines
vitiligo as a loss of skin melanocytes leading to sharply
demarcated depigmented areas, often systematically
spread. Diagnosis is made by examination, and skin
lesions are accentuated under Wood's light. The inclusion
and exclusion criteria were determined a priori. We
included trials published in any language, treating males
or females of any age and skin type. Epidemiological asso-
ciation studies, and publications where the full study
report was not available were excluded.
The included trials were assessed for design quality using
the Jadad scale [15]. Based on the Jadad scale, one point is
assigned if the study is described as randomized; one
point is given if the study is described as double blind,
and one point is awarded if there is a description of with-
drawals and dropouts in the report. Additionally, one
point is awarded if the randomization method was
described and is appropriate (e.g., random number tables
or computer generated sequence), and one final point is
awarded if the double blinding method was described and
is appropriate. If the randomization or double blinding
methods were inappropriate, one point for each inappro-
priate method is deducted. The maximum score is 5, indi-
cating a high quality trial. Previous reviews report a mean
Jadad score of 3.12 for herbal trials [16], and a mean
Jadad score of 3.2 for trials of conventional medicine [17].
A study by Klassen directly comparing the quality of CAMBMC Dermatology 2008, 8:2 http://www.biomedcentral.com/1471-5945/8/2
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(complementary and alternative medicine) and conven-
tional medicine trials reports a median Jadad score of 3 for
CAM and 2 for conventional medicine trials, citing no sig-
nificant difference between the two [18]. These findings
are consistent with another recently published study com-
paring the quality of placebo-controlled trials of western
phytotherapy with conventional medicine, which con-
cluded that the quality of phytotherapy trials was superior
to those of conventional medicine [19].
In addition to the information required to calculate the
Jadad score, the following information was extracted from
each paper: study design, number of participants, compli-
ance, inclusion and exclusion criteria, intervention, out-
come measure, results and adverse events. This
information was collected to facilitate comparison with
the Cochrane Collaboration's review of conventional bio-
medical vitiligo treatments [1].
Results
The initial search of NHP search terms and Vitiligo
resulted in 986 citations. A manual review of titles and
abstracts was conducted to identify studies appearing to
meet the inclusion and exclusion criteria which resulted
in 47 articles. The full text of these articles was obtained
and reviewed. Studies without a control group, epidemio-
logical reports, and incomplete reports were discarded.
This process resulted in 15 articles that met the inclusion
and exclusion criteria. Details of these studies are summa-
rized in Table 2.
Of the 15 trials included in this review 11 were published
in English, three in Chinese, and one in French. Trial
reports published in Polish, Russian, German, Spanish
and Italian were reviewed during the second stage of data
collection; however, these were either incomplete, did not
involve NHPs, or were uncontrolled and therefore did not
meet our inclusion criteria. Of the trials included in this
review, ten studied NHPs as an adjunct to UVA or UVB,
and five investigated NHPs as the primary treatment. We
group the clinical trials into four broad categories of NHP
interventions: L-phenylalanine, traditional Chinese med-
icine (TCM) products, herbs, and vitamins.
The most commonly studied intervention was L-phenyla-
lanine, assessed in three trials as an adjuvant to UVA or
UVB phototherapy [20,21] (Siddiqui references two trials
in one paper), and in one trial with other agents but with-
out phototherapy [22]. At doses ranging from 50 mg/kg to
100 mg/kg for 6 to 18 months, all trials reported benefi-
Table 1: Search Strategy
Databases Searched For all available years up to August 27, 2007
All EBM Reviews (Cochrane) International Pharmaceutical Abstracts
Allied and Complementary Medicine Journals@ovid Full Text
CINAHL (OVID) MEDLINE
EMBASE Ovid Helathstar
Search Terms
All items were searched individually in each database. The leucoderma and vitiligo were combined together using the OR boolean. The rest of the 
search group were combined together into a second group using the OR boolean. The first and second group were then combined using the AND 
boolean.
• Leucoderma • Inorganic chemicals
• Vitiligo • Inorganic compound
• Alternative therapies • Medicinal plant
• Amino acid • Micronutrient
• Ayurvedic • Mineral
• Biological factors • Natural health product
• Biological group • Naturopathy
• Botany • Nutrient
• Chinese herb • Nutrition
• Complementary medicine • Nutrition therapy
• Complementary therapies • Phytotherapy
• Diet therapy • Plant
• Dietary supplement • Plant extract
• Drugs, chinese herbal • Plant preparations
• Essential fatty acids • Plants, medicinal
• Ethnobotany • Traditional medicine
• Ethnopharmacology • Vitamin
• HerbB
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Table 2: Summary of Study Results
Study ID Year & 
Country
Study Design JADAD 
score (0–5)
N (n = total;
a = active;
c = control)
Dropouts Inclusion/
Exclusion Criteria
Intervention Main Outcome 
Measure
Results
Akyol 2002 [32]
Turkey
controlled 0 n = 30
a = 15
c = 15
not reported Inclusion
patients with active, 
extensive & 
generalized vitiligo
14–60 years old
skin type II, III, IV
Active
PUVA + vit E (900 IU/
day)
Control
PUVA 3x/wk, 315–400 
nm emission spect 
increased by 20% up to 
erythema
Duration: 6 months
front and back total 
body photographs
pigmentation rated as:
- bad (0–25%)
- moderate (25–74%)
- good (75% or more)
PUVA + Vit E 
allowed good 
improvement in 60% 
of patients, with no 
significant oxidation.
Active
bad 3 (20%)
moderate 3 (20%)
good 9 (60%)
Control
bad 5 (33%)
moderate 4 (27%)
good 6 (40%)
Bedi 1989 [26]
India
placebo, controlled 0 n = 32
c = "self controlled" 
placebo for 1 month 
every 3 months
2 participants lost to 
follow up
Inclusion
- male and female
- 6–42 years old
- methoxsalen tablets 
10–20 mg QD + 
methoxsalen ointment/
lotion-0.75% + P. kurroa 
rhizomes – 200 mg 
dried herb BID + 
exposure to sunlight
Duration: 36–1.8 
months; 12.13 months 
average treatment 
length
response rated as:
- 4 = complete cure
- 3 = fast & continuous 
reduction in patches
- 2 = slow, continues 
reduction in patches
- 1 = v. slow progress
- 0 = 0 progress
93% responded to 
treatment, 27% 
achieved complete 
cure.
4 = 8/30
3 = 17/30
2 = 2/30
1 = 3/30
Cheng 1987 [23]
China
randomized, 
controlled
1n  =  3 2 9
A: 16 = needle
B: 9 = medication
C: 5 = phototherapy
D: 128 = needle + 
medication
E: 61 = needle + 
medication + suntan
F: 110 = needle + 
medication + 
phototherapy
not reported not reported - needle = 1 g/2 ml 
bottle, injected 2–4 mL 
QD
- medication = 235 
used "Vitiligo 
medication"; 48 used 8-
MOP; 25 used "vitiligo 
cream"; rest prescribed 
egg yolk before suntan 
or phototherapy
- suntan = mid-May to 
end of Sept whole body 
naked suntan, 1–3 hr 
per day, 8–10 am, or 4–
6 pm
- phototherapy = long 
wave phototherapy, 
every 2–3 days 5–25 
cm2 or 1–10% of body 
surface
response rated as:
- excellent = color of 
lesion turns to normal
- very good = color of 
lesion turns normal for 
over 60% of body 
surface
- good = lesion gets 
smaller and appearance 
of black granules
- bad = lesion identical 
to that before the 
treatment
Treatment with 
suntan effective 
after 60 days.
Group A:
2 = excellent
5 = very good
9 = good
Group B
1 = excellent
2 = very good
6 = good
Group C
4 = good
1 = bad
Group F
16 = excellent
35 = very good
58 = good
1 = bad
109 = overall good 
result
Group D
8 = excellent
37 = very good
79 = good
4 = bad
124 = overall good 
result
Group E
12 = excellent
26 = very good
23 = good
61 = overall good 
result
Cormane 1985 [20]
Netherlands
controlled by run in 
over 4 months
0 n = 19 not reported Inclusion
- male and female
- generalized vitiligo
- above 18 years old
Exclusion
- past spontaneous 
improvement
- CI to phenylalanine
l-phe 50 mg/kg after a 
low protein breakfast + 
UVA 2x/wk
Duration: 6–8 months
Controlled by run in 
with l-phe 50 mg/kg 2x/
wk for 4 months
repigmentation was 
classified as dense, 
sparse or none
Repigmentation 
achieved in 94.7% of 
patients.
dense repigmentation 
in 26.3% (5 pts)
sparse 68.4% (13 pts)
none 5.2 (1 pt)B
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Jin 1983 [25]
China
randomized, 
controlled
1n  =  2 3 2
A: n = 100
B: n = 51
C: n = 52
D: n = 28
not reported not reported A: Chinese Herb/
Medicine 1
Ingredients: multi herb 
formula
B: Corticoids
15 mg per day, oral (if 
effective decrease 5 mg 
every 2–4 weeks)
C: Chinese Herb/
Medicine 2 + 
Corticoids
Ingredients different 
from Chinese Herb/
Medicine 1* Group 
A,B,C also applies 30% 
Psoralen topically
D: Control
apply 30% Psoralen 
topically
Duration: 2 months
response rated as:
- Excellent = all lesions 
disappear, normal skin 
color reappears
- Very good = 
reduction in lesion, 
>60% of damaged skin 
surface regains normal 
skin color
- Good = reduction in 
lesion, 10–60% of 
damaged skin surface 
regains normal skin 
color
- Bad = lesion shows no 
change in appearance 
or size, <10% of 
damaged skin surface 
regains normal skin 
color
Chinese medicine 2 
& corticoids 
provided the best 
treatment.
Group A
13% = excellent
17% = very good
34% = good
36% = bad
Group C
31% = excellent
14% = very good
28% = good
27% = bad
Group B
18% = excellent
13% = very good
29% = good
40% = bad
Group D
0% = excellent
6% = very good
27% = good
67% = bad
Khemis 2004 [30]
France
randomized, double 
blind
2n  =  3 0
self controlled by 
contralateral side
13 dropped out Inclusion
participants with 2 
vitiliginous lesions 
each with at least 10 
cm in diameter
Exclusion
unstable vitiligo
Active
Vitix + UVB
Control
Placebo + UVB
primary:
- reduction of lesion 
surface area by 50%
- photographs under 
normal and Woods 
Lamp
The difference 
between control and 
active was not 
significant
4 participants did not 
repigment
4 participants received 
a reduction
6 achieved a reduction 
of more than 50% of 
lesion with Vitix and 
UVB but not with 
control
3 achieved had a 
reduction of more than 
50% of lesion with 
control but not with 
Vitix and UVB.
Liu 2003 [24]
China
randomized, 
controlled
1n  =  7 4
a = 41
c = 33
not reported not reported Active
- Xiaobai mixture orally 
(30 g walnut, 10 g red 
flower, 30 g black 
sesame, 30 g black 
beans, 10 g zhi bei fu 
ping, 10 g lu lu tong, 5 
plums)1 mL is 
equivalent to 0.1 g raw 
medication, 160 mL 
once a day
Control
- 10 mg 8-MOP TID
Duration: 3 months
repigmentation rated 
as:
- Excellent = normal 
skin color reappears
- Very good = >50% of 
damaged skin surface 
regains normal skin 
color
- Good = 10–50% of 
damaged skin surface 
regains normal skin 
color
- Bad = <10% of 
damaged skin surface 
regains normal skin 
color
95% of active and 
79% of control group 
showed good 
results.
Active
- 12 = excellent results
- 16 = very good 
results
- 11 = good results
- 2 = bad results
- Overall 95.12% 
showed good results
Control
- 3 = excellent results
- 14 = very good 
results
- 9 = good results
- 7 = bad results
Table 2: Summary of Study Results (Continued)B
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Middelkamp-Hup 
2007 [28]
Netherlands
placebo controlled, 
randomized, double 
blind
5n  =  5 0
a = 25
c = 24
1 lost to follow up at 
last session
Inclusion
- 18 years and older
- vitiligo vulgaris
Exclusion
- history of skin 
cancer
- photosensitive
- pregnancy or 
lactation
- segmental vitiligo
- phototherapy 3 
months prior
- use of topical 
treatments
- starting vitamins 
during the study
Active
Polypodium leucotomos 
250 mg TID + NB-UVB 
2x/wk (210–360 j/cm2 
at start & gradually 
increased)
Control
placebo TID + NB-UVB
Duration: 25–26 weeks
severity of vitiligo rated 
as:
- very severe
- severe
- more severe
- less severe
- not so severe
secondary measures:
- digital photography of 
all vitiligo lesions
- patient self 
assessment scale 0–10
- monitored at w0, w6, 
w12, w26
- for quality of life used 
skin index-29
Clear trend toward 
increase in repig-
mentation in head 
and neck area with 
NB-UVB and oral P. 
leucotomos treat-
ment.
Percent 
Repigmentation :
Head & Neck
active = 44%
control = 27%
Extremities
active = 30%
control = 26%
Trunk
active = 36%
control = 30%
Hands and Feet
active = 24%
control = 19%
Parsad 2003 [2]
India
randomized, placebo 
controlled, double 
blind
2n  =  5 2
a = 26
c = 26
1 active
2 control
"withdrew for 
reasons unrelated to 
the study"
Inclusion
gradually progressive 
slow spreading 
vitiligo
Exclusion
more than 3 lesions 
or surface area of 
depigmentation 
greater than 10 cm2 
over last 1 month
Active
40 mg Ginkgo biloba 
with 9.6 mg 
ginkgoflavone 
glycosides, TID
Control
sugar capsule TID
Duration: 6 months
- photographs at 6-
weekly intervals
- repigmentation judged 
as minimal (25%), 
moderate (50%), 
marked (75%), 
complete (100%)- 
degree of 
repigmentation was 
determined by 
comparison of paper 
tracings, written 
descriptions, and actual 
measurement of 
vitiliginous areas
Gingko biloba was 
significantly more 
effective.
Active
-20 pts stopped 
progression of disease 
(out of 25)
- 10 pts showed 
marked to complete 
repigmentation (75–
100%) (out of 25)
Control
- 8 pts arrested 
progression of disease 
(out of 22)
- 2 pts showed marked 
to complete 
repigmentation (75–
100%) (out of 22)
Rojas-Urdaneta 2007 
[22]
Venezuela
randomized, double 
blind
3n  =  1 0 0
divided into 5 groups
all completed the 
study
Inclusion
- stable vulgar vitiligo
- no treatment for 5 
months before study
- 18 to 50 years old
- male or female
- no other pathology
- provided consent 
for study and 
treatment
Exclusion
- concomitant 
disease
- treatment of vitiligo 
5 months prior to 
study
- not complying with 
instructions
A: antioxidant and 
mitochondrial 
stimulating cream & 
oral antioxidants & 
phenylalanine
B: placebo cream and 
oral antioxidants and 
phenylalanine
C: oral administration 
of antioxidants and 
phenylalanine
D: placebo cream
E: antioxidant and 
mitochondrial 
stimulating cream
cream = VitilVenz
phenylalanine = 500 mg 
q12 hrs for 5 months
oral antioxidants = Vit 
A 20,000 IU
Vit C 1000 mg
Vit E 400 IU
Zinc 15 mg
Selenium 50 μg
Magnesium 2 mg
CoQ10 75 mcg
pygnogenol 1 mg
main outcome 
measures:
- clinical area of newly 
formed pigment every 
30 days
- point system for 
classifying size
- histological presence 
of melanocytes at 
beginning and end
The use of 
antioxidant and 
mitochondrial 
cream, and oral 
antioxidants and 
phenylalanine 
provided best 
results.
group A
- best results, 10.4 
points (p < 0.001)
group E
- second best results 
9.77 points (p < 0.001)
group B, C
- 4 points (p < 0.05)
group D
- comparison placebo 
group
Table 2: Summary of Study Results (Continued)B
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Siddiqui 1994 trial 1 
[21]
Netherlands
randomized, 
controlled, open 
label
0n  =  1 4 9
A: no tx = 11
B: l-phe +UVA = 132
C: l-phe alone = 6
out of 132 l-phe + 
UVA, 60 dropped 
out because they 
were unable to 
attend every 3 
months for 
evaluations)
Inclusion
- disseminated vitiligo 
over 10–40% of body
- age 18–61 yrs
Exclusion
- only distal vitiligo
- only acrofacial 
vitiligo
- contraindications 
(same as Carmane 
1985)
- patients in the open 
trial were not 
enrolled in the blind 
trial
A: l-phe 50–100 mg/kg 
+ UVA 2x/wk; 30–45 
min after l-phe 
ingestion daily
B: l-phe 100 mg alone
C: no tx
Duration: 1.5 yrs
length & width 
measures + color 
photographs every 3 
months
Repigmentation 
Classification:
- partial 25–40%
- incomplete 40–60%
- good 60–80%
L-phenylalanine + 
UVB provided 
better results than 
L-phenylalanine 
alone.
Group A
positive 94
stable 20
deterioration 18
n = 132
Group C
positive 0
stable 7
deterioration 4
n = 11
Group B
positive 0
stable 5
deterioration 1
n = 6
Siddiqui 1994 trial 2 
[21]
Netherlands
placebo controlled, 
randomized, double 
blind
3 n = 32 5 in placebo
3 active (2 stopped 
for personal reasons)
Inclusion
18–56 years old
vitiligo for 1–33 years
l-phe 100 mg/kg/day or 
placebo
UVA 2–3x/wk or no 
irradiation
Duration: 6 months
length and width 
measured + color 
photographs every 3 
months
Repigmentation 
Classification:
- partial 25–40%
- incomplete 40–60%
- good 60–80%
L-phenylalanine + 
UVB provided best 
results.
l-phe + UVA
positive 6
stable 1
deterioration 1
% repigmentation 30–
60
n = 8
dropouts 0
l-phe
positive 1
stable 3
deterioration 1
% repig 25
n = 5
dropouts 3
placebo + UVA
positive 0
stable 4
deterioration 2
% repig 0
n = 6
dropouts 2
placebo
positive 0
stable 3
deterioration 2
% repig 0
n = 5
dropouts 3
Tjioe 2002 [31]
Sweden
randomized, open 
label, controlled
2n  =  2 7
a = 14
c = 13
1 active and 1 
control did not 
repigment more than 
5% after 4 months 
and were advised to 
stop
Inclusion
- male & female over 
18 yrs
- stable vitiligo 
vulgaris (1 year with 
no changes)
- fitzpatrick's skin II – 
IV
Exclusion
- other vitiligo 
treatment
- history of skin 
cancer
- on photosensitizing 
medications
- Psychiatric/epileptic 
disorders
- renal failure or 
allergies to 
substances in trial
Active
- UVB 3x/wk
- oral cobalamin 1000 
ug sustained release 
BID
- folic acid 5 mg BID
Control
- UVB (311 nm) 3x/wk, 
started at 0.10 J/cm2 
increased by 0–30% on 
individual basis
Duration: 12 months
primary:
visually scored as 
percentage of 
repigmentation of 
depigmented lesions 
primary criterion were 
areas showing most 
active repigmentation
secondary:
before and after 
photographs with % 
repigmentation visually 
estimated
No significant 
difference between 
the two groups.
25 out of 27 total 
showed prominent 
repigmentation in some 
areas, 1 in each group 
did not respond more 
than 5%
Table 2: Summary of Study Results (Continued)B
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Valkova 2004 [27]
Bulgaria
controlled
(group assignment by 
alternation)
0n  =  3 3
a = 16
c = 17
not reported Inclusion
-vitiligo
- male & female and 8 
kids
- age 6–59 (mean 
24.3 years)
- photo-type II-IV
- 2–21 years of 
disease
Active
- local KUVA
- 5% khellin in water/oil 
applied to lesion area
- 1 hr later – UVA – 2–
2.5 j/cm2
Control
- systemic PUVA
- oral psoralen (0.4 mg/
kg)
- 2 hrs later-UVA – 1–
1.5 j/cm2
- 3x/wk
Duration: 4.1 months
- % of repigmentation 
measured by 
planimetry (actual 
measurement)- % 
repigmentation 
according to rule of 
three
Both KUVA and 
PUVA treatment 
lead to similar 
results, but KUVA is 
local, therefore with 
potentially with less 
adverse events.
active n
90–100% 3(18.8%)
60–80% 4(25.0%)
20–50% 7(56.2%)
no effect 2
Signs of repigmentation 
appeared between 10–
16 procedures
control n
90–100% 2 (11.8%)
60–80% 7 (41.2%)
20–50% 7 (41.2%)
no effect 1
anonymous 2006 
[29]
Japan
randomized,
double blind
0n  =  1 9
a = 10
c = 9
not reported Inclusion
generalized vitiligo
Exclusion
acral or segmental 
vitiligo
Active
PUVA + Polypodium 
leucotomos
Control
PUVA + placebo
Duration: 12 wks
repigmentation scored 
as:
- none or minimal 
(<25% repigmentation)
- mild (25–50%)
- moderate to excellent 
(>50%)
Percentage of 
patients with skin 
repig. greater than 
50% was significantly 
higher in PUVA + 
Polypodium
active
none = 2
mild = 3
moderate = 5
Control
none = 5
mild = 4
moderate = 0
Table 2: Summary of Study Results (Continued)BMC Dermatology 2008, 8:2 http://www.biomedcentral.com/1471-5945/8/2
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cial effects. The studies recruited from 19 to 149 patients.
Two of the studies had a Jadad score of 0, and two had a
Jadad score of 3. The main problems were lack of rand-
omization and poor control in two studies, high partici-
pant dropout in another trial, and inconsistent outcome
measures. It is not possible to pool the data from the stud-
ies for meta-analytic purposes due to the wide differences
in outcome measures. Overall there is moderate evidence
that L-phenylalanine has efficacy as an adjunctive agent to
phototherapy. Additional controlled research that focuses
on L-phenylalanine in conjunction with UVA or UVB
phototherapy is necessary to confirm these preliminary
findings.
Three trials used traditional Chinese medicinal herbs for
the treatment of vitiligo [23-25]. Each clinical trial used
different remedies, some given by themselves, or in con-
junction with phototherapy or sun tan advice. Specifi-
cally, Liu used a Xiaobai mixture containing walnut, red
flower, black sesame, black beans, zhi bei fu ping, lu lu
tong, and plums; details of the products investigated were
not provided for the other two trials. All three trials com-
pared the NHP intervention to conventional biomedical
treatments of vitiligo (phototherapy, corticosteroids, or
psoralen) in the control group. The studies ranged from
74 to 329 patients and 2–3 months. Even though two of
the studies are relatively large (329 and 232 participants),
participants were divided into multiple groups. No further
details of group allocation are provided. All three trials
indicate positive results for the NHP intervention. All
three trials received a Jadad score of 1. Varying and poorly
described treatments, small treatment group size, and
inconsistent outcome measures were the main problems
with the studies. It is not possible to pool the data from
the studies for meta-analytic purposes due to the varying
treatments and differences in outcome measures. Overall,
there is weak evidence that some traditional Chinese
medicinal herbs may be useful for the treatment of vitil-
igo. None of the treatments' effects have been replicated
and overall the studies are of poor methodological qual-
ity.
Six trials investigated the use of plants in the treatment of
vitiligo. Four of these trials utilized plants as photosensi-
tizing agents (Picorrhiza kurroa, a khellin extract, and two
Polypodium leucotomos) [26-29] all given orally in conjunc-
tion with UVA or UVB phototherapy; one investigated the
use of oral Ginkgo biloba by itself (40 mg TID) [2]; and one
investigated the topical use of an extract of Cucumis melo
[30]. Treatments lasted from 3 to 12 months, and the
studies were small, ranging from 9 to 50 participants.
Only one trial by Middelkamp-Hup utilising Polypodium
leucotomos was of good quality, scoring 5 on the Jadad
scale, while the quality of the other four trials was poor,
reflected by Jadad scores ranging from 0 to 2. The main
problems with the studies were the small sample size,
poor study design, and inconsistent outcome measures.
Overall, there is weak evidence that photosensitizing
plants can be effective in conjunction with phototherapy,
and moderate evidence that Ginkgo biloba by itself can be
useful for vitiligo. Cucumis melo treatment was not found
to be statistically significant over placebo cream. Addi-
tional research to confirm these preliminary trials is nec-
essary.
Two trials investigated the use of vitamins as adjuvants to
UVA or UVB phototherapy [31,32]. Oral cobalamin
(1000 mcg BID) and folic acid (5 mg BID) were given in
one trial, and oral vitamin E was given in another (900 IU,
type of vitamin E not specified). After 12 months of treat-
ment the cobalamin and folic acid study reported no sig-
nificant difference compared to a phototherapy control.
On the other hand, 6 months of treatment with combined
vitamin E and phototherapy achieved significantly better
repigmentation than phototherapy only. The studies were
small, ranging from 27 to 30 participants, and neither had
a Jadad score greater than 2. There was a lack of statistical
information, and inconsistent outcome measures were
used. Overall, there is no evidence for using oral cobala-
min and folic acid with phototherapy for the treatment of
vitiligo, while the evidence for vitamin E as an adjunct to
phototherapy is weak.
Only five trials discussed adverse events, the most com-
mon of which were erythema, pruritis, and nausea. Ery-
thema was reported in studies utilizing phototherapy.
Pruritis was reported in trials using metoxsalen with Picor-
rhiza kurroa and Polypodium leucotomos with phototherapy.
Nausea and gastrointestinal complaints were reported in
trials utilizing Ginkgo biloba, P. leucotomos with photother-
apy, and Vitamin E with phototherapy. It is difficult to
ascertain whether the NHPs or their concomitant treat-
ments caused these adverse reactions. All reported adverse
reactions were minor. Most studies did not adequately
report adverse events, and the small sample size of the tri-
als makes generalizations difficult. A complete list of
adverse events reported is in Table 3.
Discussion
Most of the clinical trials identified were uncontrolled,
and thus could not be included in this review. Of the con-
trolled clinical trials reviewed, most were of poor method-
ological quality with only one trial receiving a Jadad score
of four or greater, and 13 receiving a score of three or less.
Only five trials could be classified as randomized control-
led trials. We found that most of the studies were poorly
reported, often lacking information on dosage frequency,
dosage strength, participant withdrawal, statistical analy-
ses and randomization. Few were double blind, and there
is no mention of compliance in any report. These findingsBMC Dermatology 2008, 8:2 http://www.biomedcentral.com/1471-5945/8/2
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are consistent with the poor quality of vitiligo trials of
conventional biomedical treatments, as discussed in the
systematic review by Whitton [1] for the Cochrane collab-
oration.
Whitton [1] also expressed concern with the lack of com-
mon, reliable outcome parameters and the variation of
methods for scoring repigmentation. Our findings mirror
this problem. We found that most NHP trials set several
repigmentation ranges and measured the number of par-
ticipants falling into each category at the end of treatment.
These repigmentation ranges seem to be arbitrary and vary
between trials, making data pooling and comparing
results across treatments difficult.
Further clinical research in the treatment of vitiligo is nec-
essary. Two areas are particularly intriguing. First, well
designed clinical trials should attempt to replicate the
studies utilizing L-phenylalanine in conjunction with
phototherapy treatment. Several small clinical trials pub-
lished so far provide positive results consistently with rep-
lication, but larger more definitive trials are necessary.
Second, the use of Ginkgo biloba alone for the treatment of
vitiligo holds potential promise. The use of Gingko biloba
without phototherapy is likely to avoid the adverse reac-
tions and unknown long term risks associated with pho-
totherapy. If effective, Ginko biloba would also be a less
costly and easier treatment for vitiligo. Parsaud's trial is
methodologically sound, and provides promising results.
However, one published trial is not enough evidence to
impact clinical practice. The need to find a safe and effec-
tive treatment is particularly important with vitiligo,
where up to 50% of cases develop in the paediatric popu-
lation; at a time when the condition has the greatest
impact on psychological development.
The poor quality of vitiligo trials has been recognized. Sev-
eral validated vitiligo outcome measures have recently
been suggested and should be utilized in future clinical
trials. One such measure is the Vitiligo Area Scoring Index
(VASI) which takes into account both the lesion area and
the intensity of depigmentation [33]. An even more pre-
cise measurement of vitiligo has been described by the
Vitiligo European Task Force [34]. The first component
summarizes relevant disease and patient information,
while the second component is an assessment system
evaluating the extent of depigmentation using the rule of
9's. (The rule of 9's is a quick way of estimating the
affected skin's surface area, where the palm is 1% of the
surface area; arms, and face & scalp are each 9% of the sur-
face area; and legs, the back, and front are 18% each). In
addition, the disease is staged based on cutaneous and
hair pigmentation of the largest lesion in each body area,
and ranked on a scale from 0–4. Assessment of spreading
is based on a Wood's lamp examination of the largest
lesion in each body area. The clinical use of this system
has been evaluated by several European University clinics,
and has showed good internal reliability [34]. Future trials
should also differentiate and evaluate vitiligo treatments
among their ability to induce stability, thus arresting fur-
ther depigmentation, and repigmentation.
Our review is limited by the poor quality of the clinical tri-
als. While there are many published clinical trials using
NHPs for the treatment of vitiligo, there is a lack of rand-
omized clinical trials. The different NHPs tested, and the
variability of the outcome measures make it impossible to
pool any data. Many trials seem to be explorative trials,
with no published follow up investigations replicating the
findings.
Conclusion
Reports investigating the efficacy of NHPs for vitiligo
exist, but are of poor methodological quality and contain
significant reporting flaws. Most trials use NHPs as an
adjunct to UVA or UVB phototherapy. There are few con-
trolled trials assessing efficacy of NHPs for vitiligo, but
those that have been published generally show weakly
positive outcomes with few adverse reactions. L-phenyla-
lanine used with phototherapy shows promise. The use of
oral  Ginkgo biloba as monotherapy for vitiligo is also
promising. Ginkgo's apparent efficacy without the need
Table 3: Adverse Events
Study ID Intervention Adverse Events
Akyol 2002 [32] vit E + UVA
vs UVA
erythema, nausea, headaches in both groups
Bedi 1989 [26] methoxsalen + Picorrhiza kurroa
vs methoxsalen
pruritis in "some cases", "no long term side effects"
Middelkamp-Hup 2007 [28] Polypodium leucotomos + UVB
vs UVB
mild transient itching (10 active, 5 control); dryness of skin (5 active, 3 control); 
mild gastrointestinal complaints (4 active, 5 control)
Parsad 2003 [2] Ginko biloba
vs placebo
2 subjects experienced nausea
Tjioe 2002 [31] UVB+cobalamin+folic acid
vs UVB
transient erythema in all patients within 24 hrs of phototherapy, prickling sensation 
at site of erythemaBMC Dermatology 2008, 8:2 http://www.biomedcentral.com/1471-5945/8/2
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for phototherapy, thus eliminating the adverse events
inherent with phototherapy make it a therapeutic option
worth investigating. Further high quality investigations
into the use of NHPs in the treatment of vitiligo, particu-
larly L-phenylalanine and Ginkgo biloba are needed.
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